Inhibition of AXL dependent non-professional efferocytosis sensitizes pancreatic cancer to immune checkpoint blockade

Abstract AXL, a receptor tyrosine kinase, is upregulated in the majority of pancreatic adenocarcinoma (PDAC) and is associated with aggressive tumor behavior. Canonically, AXL is essential for efferocytosis, or the immunologically silent phagocytic clearance of apoptotic cells. While crucial to ensure self-tolerance, efferocytosis in cancer removes tumor antigens and dampens the antitumor response to create a pro-tumorigenic environment. Here, we show that PDAC cells co-opt the AXL pathway to act as non-professional efferocytes and clear chemotherapy induced apoptotic cells from their environment in vitro and in vivo. Inhibition of AXL with the selective inhibitor BGB324 inhibits efferocytosis and increases apoptotic cell burden, immunogenic cell death, and CD8 T cell infiltration in gemcitabine treated tumors in vivo. Single cell RNA expression analysis reveal that AXL inhibited gemcitabine treated tumors are enriched in the immunecheckpoint responsive TCF1+ CD8 T cells and respond to anti-PD1 therapy in vivo. We establish a novel ability of pancreatic cancer cells to engage in non-professional efferocytosis in response to chemotherapy. Inhibiting this response can be leveraged to sensitize this classically immune quiescent cancer to immunotherapy. - Pancreatic Cancer - Innate Immunity - Phagocytosis - Efferocytosis Competing Interest Statement The authors have declared no competing interest.